Novartis AG
Switzerland
Although it's based in neutral Switzerland, Novartis has been aggressive in attacking illnesses on multiple fronts, including pharmaceuticals and vaccines. One of the world's largest pharmaceuticals, the company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars, and ophthalmic products. The company's Innovative Medicines segment develops and manufactures prescription drugs for blood pressure, cancer, and other ailments. Its Sandoz segment is among the largest manufacturers of generic drugs in the world; it also makes APIs. Novartis generates most of its revenue from international customers.
Financial Statements
Financial data as of December 31, 2020 (12 month period) in USD
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
| Cash Flow (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Net Operating Cash | $13,650 | $13,625 | $14,272 |
| Net Investing Cash | -$13,182 | -$2,226 | -$5,591 |
| Net Financing Cash | -$2,208 | -$13,627 | -$4,244 |
| Net Change in Cash | -$1,740 | -$2,228 | $4,437 |
| Cash at Beginning of Period | $11,112 | $13,271 | $8,860 |
| Cash at End of Period | $9,658 | $11,112 | $13,271 |
| Capital Expenditure | -$2,585 | -$2,257 | -$2,648 |
| Assets (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $9,658 | $11,112 | $13,271 |
| Accounts Receivable | $8,217 | $8,301 | $8,727 |
| Inventories | $7,242 | $6,092 | $6,956 |
| Other Current Assets | $4,556 | $3,999 | $6,609 |
| Asset Summary | |||
| TOTAL CURRENT ASSETS | $29,673 | $29,504 | $35,563 |
| Tangible Fixed Assets | $13,939 | $13,746 | $15,696 |
| Intangible Assets | $36,809 | $28,787 | $38,719 |
| Total Assets | $132,059 | $118,370 | $145,563 |
| Liabilities (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $5,403 | $5,424 | $5,556 |
| Short-Term Debt | $9,591 | $6,846 | $9,620 |
| Other Current Liabilities | $18,065 | $15,994 | $14,431 |
| Liability Summary | |||
| Total Current Liabilities | $33,059 | $28,264 | $29,607 |
| Long-Term Debt | $26,259 | $20,353 | $22,470 |
| Other Long-Term Liabilities | $1,393 | $1,213 | $1,371 |
| Total Liabilities | $75,393 | $62,819 | $66,871 |
| Stakeholder's Equity (mil) | 2020 | 2019 | 2018 |
|---|---|---|---|
| Equity | |||
| Common Stock | $913 | $936 | $944 |
| Retained Earnings | $ | $ | $ |
| Equity Summary | |||
| Total Equity | $56,598 | $55,474 | $78,614 |
| Shares Outstanding | 2,256,822,048 | 2,265,008,488 | 2,311,171,429 |
Credit Reports
See detailed business credit reports on other businesses or your own.
Competitor Profiles
See detailed profiles for insights and prospects on this company's top competitors.
Company Snapshot
Essential information for a successful call
-
EMPLOYEES (This Site)
40
-
EMPLOYEES (All Sites)
105,794
- ASSETS (MIL USD) 132,059
-
REVENUE (MIL USD)
49,898
- TICKER SYMBOL NOVN
- Year Started 1885
- Incorporated 1996
- FISCAL YEAR END DEC
- SALES GROWTH % 2.51%
Similar Companies Nearby
Get in Touch with 28 Principals*
-
Vasant Kalathur NarasimhanManaging Director and Chairperson
-
Hans Jörg ReinhardtChairman of the Board
-
Enrico VanniVice Chairman of the Board
-
Anthonius Christianus Maria Augustinus BüchnerMember of the Board of Directors
Want more contacts like these available directly in your inbox? Install D&B Email IQ to access your next prospects!
Related Products
Get full access to D&B Hoovers
With a Hoovers subscription you can get a comprehensive view of Novartis AG
Novartis AG*
Don't miss your chance for 50 free email contacts and prospecting data right inside of your inbox.